Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Index by author

November 01, 1985; Volume 28,Issue 5
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

B

  1. Berger, F G

    1. You have access
      Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;
  2. Berger, S H

    1. You have access
      Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;
  3. Brasier, R S

    1. You have access
      Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;
  4. Burch, M

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;
  5. Bylund, D B

    1. You have access
      Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

C

  1. Culver, P

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;
  2. Cysyk, R L

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

D

  1. Davies, H W

    1. You have access
      Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;
  2. Drendel, W B

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

E

  1. Ebetino, F H

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;
  2. Ehlert, F J

    1. You have access
      The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium.
      F J Ehlert
      Molecular Pharmacology November 1985, 28 (5) 410-421;

F

  1. Fenical, W

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

G

  1. Gantzos, R D

    1. You have access
      Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;
  2. George, S R

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
  3. Gillette, J R

    1. You have access
      Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;
  4. Glover, E

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;
  5. Grigoriadis, D

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

H

  1. Henley, J M

    1. You have access
      Epinephrine-stimulated maintained rubidium efflux from guinea pig hepatocytes may involve alpha 1- and alpha 2-adrenoceptors.
      J M Henley
      Molecular Pharmacology November 1985, 28 (5) 431-435;
  2. Hosey, M M

    1. You have access
      Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
      K K McMahon and M M Hosey
      Molecular Pharmacology November 1985, 28 (5) 400-409;

J

  1. Jenh, C H

    1. You have access
      Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;
  2. Johnson, L F

    1. You have access
      Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells.
      S H Berger, C H Jenh, L F Johnson and F G Berger
      Molecular Pharmacology November 1985, 28 (5) 461-467;

K

  1. Karle, J M

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;
  2. Kende, A S

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;

M

  1. Malinowski, N

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;
  2. Malspeis, L

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;
  3. Marquez, V E

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;
  4. McMahon, K K

    1. You have access
      Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
      K K McMahon and M M Hosey
      Molecular Pharmacology November 1985, 28 (5) 400-409;
  5. Moyer, J D

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;

N

  1. Neubig, R R

    1. You have access
      Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
      R R Neubig, R D Gantzos and R S Brasier
      Molecular Pharmacology November 1985, 28 (5) 475-486;
  2. Neumeyer, J L

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
  3. Nilsson, J L

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

P

  1. Pohl, L R

    1. You have access
      Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;
  2. Poland, A

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;
  3. Potenza, C

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;

R

  1. Ray-Prenger, C

    1. You have access
      Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

S

  1. Salam, M A

    1. You have access
      Inhibition of uridine kinase and the salvage of uridine by modified pyrimidine nucleosides.
      J D Moyer, J M Karle, N Malinowski, V E Marquez, M A Salam, L Malspeis and R L Cysyk
      Molecular Pharmacology November 1985, 28 (5) 454-460;
  2. Satoh, H

    1. You have access
      Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;
  3. Schulick, R D

    1. You have access
      Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats.
      H Satoh, J R Gillette, H W Davies, R D Schulick and L R Pohl
      Molecular Pharmacology November 1985, 28 (5) 468-474;
  4. Seeman, P

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
  5. Sundaralingam, M

    1. You have access
      Structure-activity relationship of bispyridyloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. Chemical, biological, and X-ray crystallographic studies.
      A S Kende, F H Ebetino, W B Drendel, M Sundaralingam, E Glover and A Poland
      Molecular Pharmacology November 1985, 28 (5) 445-453;
  6. Svensson, U

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;

T

  1. Taylor, P

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;
  2. Tedesco, J L

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
  3. Turner, J T

    1. You have access
      Alpha 2-adrenergic receptors in the human cell line, HT29. Characterization with the full agonist radioligand [3H]UK-14,304 and inhibition of adenylate cyclase.
      J T Turner, C Ray-Prenger and D B Bylund
      Molecular Pharmacology November 1985, 28 (5) 422-430;

W

  1. Wasserman, L

    1. You have access
      Structure-activity relationships for the irreversible blockade of nicotinic receptor agonist sites by lophotoxin and congeneric diterpene lactones.
      P Culver, M Burch, C Potenza, L Wasserman, W Fenical and P Taylor
      Molecular Pharmacology November 1985, 28 (5) 436-444;
  2. Watanabe, M

    1. You have access
      Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
      P Seeman, M Watanabe, D Grigoriadis, J L Tedesco, S R George, U Svensson, J L Nilsson and J L Neumeyer
      Molecular Pharmacology November 1985, 28 (5) 391-399;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 28, Issue 5
1 Nov 1985
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics